Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 2908-71-6 Chemical Structure| 2908-71-6

Structure of 2908-71-6

Chemical Structure| 2908-71-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 2908-71-6 ]

CAS No. :2908-71-6
Formula : C6H9Br2N3
M.W : 282.96
SMILES Code : NC1=NC(C)=NC=C1CBr.[H]Br
MDL No. :MFCD05149311
InChI Key :NZXPJPYPDFCVTK-UHFFFAOYSA-N
Pubchem ID :12513493

Safety of [ 2908-71-6 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H314
Precautionary Statements:P264-P270-P271-P280-P303+P361+P353-P304+P340-P305+P351+P338-P310-P330-P331-P363-P403+P233-P501
Class:8
UN#:3261
Packing Group:

Computational Chemistry of [ 2908-71-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.33
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 54.28
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

51.8 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.78
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.08
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.07
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.6
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.3

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.05
Solubility 0.25 mg/ml ; 0.000884 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.49
Solubility 0.924 mg/ml ; 0.00327 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.94
Solubility 0.323 mg/ml ; 0.00114 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.76 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.14

Application In Synthesis of [ 2908-71-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 2908-71-6 ]

[ 2908-71-6 ] Synthesis Path-Downstream   1~48

  • 2
  • [ 110-86-1 ]
  • [ 2908-71-6 ]
  • [ 109162-61-0 ]
  • 3
  • [ 3581-91-7 ]
  • [ 2908-71-6 ]
  • 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-4,5-dimethyl-thiazolium; bromide hydrobromide [ No CAS ]
  • 4
  • [ 91-22-5 ]
  • [ 2908-71-6 ]
  • [ 97496-59-8 ]
  • 5
  • [ 120-72-9 ]
  • [ 2908-71-6 ]
  • 5-indol-1-ylmethyl-2-methyl-pyrimidin-4-ylamine [ No CAS ]
  • 6
  • [ 7036-04-6 ]
  • [ 2908-71-6 ]
  • 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-4-hydroxymethyl-thiazolium; bromide hydrobromide [ No CAS ]
  • 7
  • [ 59-67-6 ]
  • [ 2908-71-6 ]
  • 1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-3-carboxy-pyridinium; bromide hydrobromide [ No CAS ]
  • 8
  • [ 103-74-2 ]
  • [ 2908-71-6 ]
  • 1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-2-(2-hydroxy-ethyl)-pyridinium; bromide hydrobromide [ No CAS ]
  • 13
  • <i>N</i>-[2-(4-methyl-thiazol-5-yl)-ethyl]-formamide [ No CAS ]
  • [ 2908-71-6 ]
  • 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-(2-formylamino-ethyl)-4-methyl-thiazolium; bromide hydrobromide [ No CAS ]
  • 15
  • benzylidene-[2-(4-methyl-thiazol-5-yl)-ethyl]-amine [ No CAS ]
  • [ 2908-71-6 ]
  • 5-(2-amino-ethyl)-3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-4-methyl-thiazolium; bromide monohydrobromide [ No CAS ]
  • 17
  • [ 2908-71-6 ]
  • [ 118-92-3 ]
  • <i>N</i>-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-anthranilic acid [ No CAS ]
  • 18
  • [ 2908-71-6 ]
  • [ 88-74-4 ]
  • 2-methyl-5-(2-nitro-anilinomethyl)-pyrimidin-4-ylamine [ No CAS ]
  • 19
  • [ 2908-71-6 ]
  • [ 62-53-3 ]
  • [ 1886-29-9 ]
  • 20
  • [ 289-06-5 ]
  • [ 2908-71-6 ]
  • [ 27497-91-2 ]
  • 21
  • [ 693-95-8 ]
  • [ 2908-71-6 ]
  • [ 54918-60-4 ]
  • 22
  • [ 100114-47-4 ]
  • [ 2908-71-6 ]
  • 4-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-3-methyl-[1,2,4]thiadiazolium; bromide hydrobromide [ No CAS ]
  • 23
  • [ 4291-14-9 ]
  • [ 2908-71-6 ]
  • [ 27497-92-3 ]
  • 24
  • [ 3292-59-9 ]
  • [ 2908-71-6 ]
  • 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-2-(1-carbamoyl-1-hydroxy-ethyl)-thiazolium; bromide [ No CAS ]
  • 25
  • [ 2606-90-8 ]
  • [ 2908-71-6 ]
  • [ 154-87-0 ]
  • 26
  • [ 2908-71-6 ]
  • [ 5664-55-1 ]
  • 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-thiazolium; bromide monohydrobromide [ No CAS ]
  • 27
  • [ 75848-79-2 ]
  • [ 2908-71-6 ]
  • [ 75848-80-5 ]
  • 28
  • [ 2908-71-6 ]
  • [ 75-65-0 ]
  • [ 127556-60-9 ]
  • 30
  • [ 2908-71-6 ]
  • <5-methyl-1(3)<i>H</i>-imidazol-4-yl>-methanol [ No CAS ]
  • [1-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-methyl-1<i>H</i>-imidazol-4-yl]-methanol; monohydrobromide [ No CAS ]
  • 31
  • [ 2908-71-6 ]
  • (+-)-3-<4-methyl-thiazol-5-yl>-propane-1,2-diol [ No CAS ]
  • 3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-5-(2,3-dihydroxy-propyl)-4-methyl-thiazolium; bromide hydrobromide [ No CAS ]
  • 32
  • [ 2908-71-6 ]
  • (+-)-2-<1-hydroxy-ethyl>-5-<2-hydroxy-ethyl>-4-methyl-thiazole [ No CAS ]
  • [ 14707-32-5 ]
  • 33
  • [ 2908-71-6 ]
  • (+-)-2-acetylamino-3-<4-methyl-thiazol-5-yl>-propionic acid [ No CAS ]
  • 5-(2-acetylamino-2-carboxy-ethyl)-3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-4-methyl-thiazolium; bromide hydrobromide [ No CAS ]
  • 34
  • [ 2908-71-6 ]
  • [ 13100-57-7 ]
  • 35
  • [ 2908-71-6 ]
  • [ 74581-81-0 ]
  • 36
  • [ 2908-71-6 ]
  • [ 28742-07-6 ]
  • 37
  • [ 2908-71-6 ]
  • [ 27374-34-1 ]
  • 38
  • [ 2908-71-6 ]
  • [ 28742-12-3 ]
  • 39
  • [ 2908-71-6 ]
  • [ 27512-93-2 ]
  • 40
  • [ 2908-71-6 ]
  • [ 25626-40-8 ]
  • 41
  • [ 2908-71-6 ]
  • [ 25626-38-4 ]
  • 42
  • [ 2908-71-6 ]
  • [ 25626-41-9 ]
  • 43
  • C5(11)CH9NOS [ No CAS ]
  • [ 2908-71-6 ]
  • [11C]-thiamine [ No CAS ]
YieldReaction ConditionsOperation in experiment
25% In 1-methyl-pyrrolidin-2-one; N,N-dimethyl-formamide; at 130℃; for 0.166667h;Inert atmosphere; On the o ther hand, trisdibenzylieneacetone dipalladium (1.1 mg, 1.2 **mol) and the NMPsolution (200 muL) of triotolyl phosphine (5.8 mg, 19.1 **mol) were prepared for thereaction container of the sign synthesizer unit, and it installed in the room temperature. Thesolution in a reaction container was installed in 10 20 quota which blows a [ C] methyliodide. Then, a [ C] methyl iodide is blown into a reaction container by the gas mass flow of6080 mL/min, The NMP solution (100 muL) of the tin precursor 2 (5.0 mg, 11.9 **mol), CuBr(0.9 mg, 5.9 **mol), and CsF (2.3 mg, 14.9 **mol) was added there, and it heated for 3minutes at 100 degrees C. Then, the DMF solution (100 **L) of 4amino5(bromomethyl)2methylpyrimidine bromate (50 mg, 176.7 **mol) was added, and it heated for 7 minutes at150 degrees C, blowing nitrogen gas by the flow rate of 20 mL/min. After diluting the obtainedreaction solution with the washing liquid (acetonitrile: water =1:1) of 1.2 mL, it filtered usingthe filter. The fraction which presents preparative isolation HPLC with a filtrate (refer to Fig.1),and contains the Csign thiamin 4 isolated preparatively was concentrated in vacuum in theevaporator. Preparative isolation HPLC was again presented with the filtrate obtained bycarrying out filter filtration of the concentrate (refer to Fig.2). The fraction containing the 11C-thiamin 4 isolated preparatively was put into the membrane filter at the sterile vialthrough the concentrate obtained by concentrating in vacuum in an evaporator.
  • 44
  • [ 769-82-4 ]
  • [ 2908-71-6 ]
YieldReaction ConditionsOperation in experiment
87% With hydrogen bromide; In acetic acid; at 100℃; S4. Add 100 grams of ring-closing product to a 1-liter jar.Slowly add 500 ml of 33% HBr/HOAc solution.Slowly warm the system to 100C,Maintain this temperature for 8-16 hours,TLC determines the endpoint of the reaction.After the reaction is completed, 20 grams of acidic activated carbon is added while hot, and the mixture is stirred for 30 minutes and then filtered. The filtrate is concentrated under pressure and dried to dryness. 30 milliliters of anhydrous ethanol is added, and the crystals are cooled and filtered.149 g of the target product was dried to give a yield of 87%.
  • 45
  • [ 73-66-5 ]
  • [ 2908-71-6 ]
YieldReaction ConditionsOperation in experiment
81% With hydrogen bromide; acetic acid; at 20 - 100℃; for 2.0h; 2-methyl-5-ethoxymethyl-6-aminopyrimidine (1.1 g, 6.6 mmol) was fed to a 200 mL one-neck flask, and then a HBr solution in acetic acid (10%, 73 mL) was added, heated to 100C., and reacted for 2 hrs. The reaction was cooled to room temperature (where during the reaction, the solid was dissolved first, and then a solid was produced gradually). The reaction solution was suctioned, washed with diethyl ether, and recrystallized twice in methanol/anhydrous diethyl ether, to obtain a white solid (1.5 g, yield 81%). 1H NMR (300 MHz, DMSO-d6) delta: 9.31 (s, 1H), 8.62 (s, 1H), 8.50 (s, 1H), 4.67 (s, 2H), 2.49 (s, 3H). MS (ESI): m/z 202 (M+1, 20), 154 (M-Br+OCH3, 100).
  • 46
  • 2-methyl-5-ethoxymethyl-6-hydroxypyrimidine [ No CAS ]
  • [ 2908-71-6 ]
  • 47
  • [ 749835-80-1 ]
  • [ 2908-71-6 ]
  • 48
  • 5-(2-[18F]fluoroethyl)-4-methylthiazole [ No CAS ]
  • [ 2908-71-6 ]
  • C12H16(18)FN4S(1+)*Br(1-)*BrH [ No CAS ]
YieldReaction ConditionsOperation in experiment
In acetonitrile; at 110℃; for 0.333333h; The preparative peak of 5-(2-fluoroethyl)-4-methylthiazole was collected in an extraction flask containing diethyl ether (20 mL) and sodium chloride (6.6 g), during which the extraction flask (sodium chloride was used to saturate water in mobile phase) was stirred with a rotor. After collection, the stirring was continued for additional 1 min, then the solution in extraction flask was stood for 1 min, and the supernatant diethyl ether phase was transferred to an intermediate flask. The diethyl ether was transferred from the intermediate flask to the reaction vial 2 where the temperature was set to 55C., and diethyl ether was evaporated to dryness over 12 min under a stream of nitrogen. After 12 min of evaporation, acetonitrile (1 mL) was added into the reaction vial 2 to dissolve the 5-(2-fluoroethyl)-4-methylthiazole, stirred for 10 sec and then passed through a magnesium sulfate column. Additional acetonitrile (1 mL) was added to rinse the reaction vial 2 and elute the 5-(2-fluoroethyl)-4-methylthiazole off from the magnesium sulfate column. The acetonitrile solution flowing through the magnesium sulfate column was transferred back to the reaction vial 2. Precursor II (5 mg, previously dissolved in 1 mL hot acetonitrile) was added, and reacted for 20 min at 110C. while the reaction vial 2 was sealed, to obtain a 18F substituted thiamine product. At the same time, the sample injector was washed with methanol repeatedly. In the heating process during the reaction, a nitrogen stream was blown to reduce the volume of the solvent acetonitrile. When the temperature reached 110C., the nitrogen stream was shut off, and the reaction vial 2 was sealed. After reaction, the system was maintained at 110C. for 3 min, during which a nitrogen stream was blown to contribute to evaporate the acetonitrile to dryness, and then the system was cooled to RT. After cooling to RT, water (0.5 mL) was added, stirred for 20 sec to dissolve 18F substituted thiamine, and then transferred to the sample injector for separating and collecting a pure 18F substituted thiamine product by preparative chromatography. Conditions for preparative chromatography: Waters Xbridge C18 preparative column (19100 mm, 5 um), mobile phase: 5% methanol/95% water (containing 50 mM ammonium acetate); flow rate: 14 mL/min. The desired liquid phase peak was collected based on the signal from a radio-detector, where the 18F substituted thiamine retention time was 6.5 min, and the collection was completed in 30 sec.
 

Historical Records

Technical Information

Categories

Similar Product of
[ 2908-71-6 ]

Chemical Structure| 25526-81-2

A518756 [25526-81-2]

5-(Bromomethyl)-2-methylpyrimidin-4-amine

Reason: Free-salt